News

Oncolytic virus immunotherapy shows promise in HR+/HER2- breast cancer trial
The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...
Science Daily15h
COVID-19 protein triggers immune attacks on healthy cells — but a common drug can stop it
Scientists have uncovered a stealthy tactic used by the SARS-CoV-2 virus: one of its proteins can leap from infected cells to ...
Sickle Cell Disease News17h
BEAM-101 shows sustained benefits as treatment for sickle cell
BEAM-101, a treatment for sickle cell disease, showed sustained efficacy and safety over one year in the BEACON Phase 1/2 ...
DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming ...
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer ...
PipelineReview.com21h
Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
OSAKA, Japan & BOSTON, MA, USA I June 23, 2025 I Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) and ...
Targeted Oncology1d
FDA Clears IND for Phase 1 Study of Lonitoclax in Relapsed/Refractory AML
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Pharmabiz1d
US FDA clears Lomond Therapeutics’ IND application for phase 1 multicenter study of lonitoclax in patients with relapsed/refractory AML
US FDA clears Lomond Therapeutics’ IND application for phase 1 multicenter study of lonitoclax in patients with relapsed/refractory AML: Dover, Delaware Monday, June 23, 2025, 1 ...
eLife2d
HIV-specific CD8+ T-cell responses soon after treatment initiation during acute HIV infection are associated with viral reservoir decline
Antiretroviral therapy (ART) initiated in the acute phase of HIV infection (AHI) results in a smaller viral reservoir. However, the impact of early HIV-specific T-cell responses on long-term reservoir ...